Figure 8 | Scientific Reports

Figure 8

From: Comprehensive analysis of Epha10 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in non-small cell lung cancer

Figure 8

Validation of the oncogenic role of EphA10 in NSCLC. (A) and (B) Expression of EphA10 in tissue samples by qRT-PCR. (C) Expression of EphA10 in normal lung tissue and NSCLC tissue samples by IHC staining. (D) and (E) The mRNA level of EphA10 was downregulated in EphA10-knockdown cells. (F) The protein level of EphA10 was downregulated in EphA10-knockdown cells. (G) and (H) CCK-8 assays were performed to analyse cell proliferation. (I) and (J) Clonogenic assays were performed to assess cell proliferation. (K) and (L) Transwell assays were performed to analyse cell motility. ***p < 0.001, **p < 0.01, *p < 0.05.

Back to article page